Pending — not yet graded
“Upgraded Gland Pharma to 'buy' from 'hold' on August 11, setting a target of ₹3,350 per share, which implies a 17.9% upside from current levels. The upgrade indicates a positive view on the stock's potential.”
Jefferies Analysis’s track record: 3 graded calls · 95% CI 44–100%
Gland PharmaBullishCalled 20 Aug 2026
This call hasn't reached its evaluation window yet — the HIT/MISS verdict will appear here once it's graded against real price data. Save it above to find it again from your profile.